
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp experienced a notable increase in total revenue for the full year 2024, reaching $83.8 million, representing a 22% growth from the previous year, with domestic revenue rising by 23% and international revenue increasing by 20%. The company's innovative solutions, including the Zephyr Endobronchial Valve and the Chartis Pulmonary Assessment System, are enhanced by improved reimbursement coverage and advancements in patient selection technologies, which contribute to a broader market potential and adoption. Additionally, the consistent long-term benefits demonstrated by Pulmonx's treatments strengthen physician confidence and support the company's expanding market penetration, particularly in the United States.
Bears say
Pulmonx Corp reported a quarterly gross profit of $17.6 million, resulting in a gross margin decrease to 74%, reflecting slight erosion compared to the previous quarter. The company's cash position declined from $107.8 million to $101.5 million over three months, suggesting potential liquidity concerns that could affect operational flexibility. Additionally, as a small-cap company operating in a high-risk medical technology sector, Pulmonx faces significant volatility, which could deter risk-averse investors amid ongoing challenges in addressing the needs of the growing COPD patient population.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares